Bibliography
- Yamada T. Therapeutic monoclonal antibodies. Keio J Med 2011;2:37-46
- Stone MJ. Monoclonal antibodies in the prehybridoma era: a brief historical perspective and personal reminiscence. Clin Lymphoma 2001;2:148-54
- Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7
- Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984;81:6851-5
- Reichert JM. Marketed therapeutic antibodies compendium. mAbs 2012;4:413-15
- Winter G, Harris WJ. Humanized antibodies. Trends Pharmacol Sci 1993;14:139-43
- Martin PL, Bugelski PJ. Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets. Br J Pharmacol 2012;166:806-22
- Bugelski PJ, Martin PL. Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. Br J Pharmacol 2012;166:823-46
- Harrison JL, Williams SC, Winter G, Nissim A. Screening of phage antibody libraries. Methods Enzymol 1996;267:83-109
- Lonberg N. Human monoclonal antibodies from transgenic mice. Handbook Exp Pharmacol 2008;181:69-97
- Buss NAPS, Henderson SJ, McFarlane M, Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 2012;12:615-22
- Topalian SL, Hodi FS, Brahmer JR, Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54
- Brahmer JR, Tykodi SS, Chow LQ, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65